China
Skincare Tech Brand AMIRO Receives QTL Certification from SGS to Strengthen R&D Efforts
AMIRO ("the Company"), a leading beauty and skincare technology brand, is thrilled to announce that its research facility, AMIRO LAB, has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by SGS.
Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, took part in the 2023 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in California between July 25-27.
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) .
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the BTIG Virtual Biotechnology Conference on August 7 - 8.
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023.
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment for the China open-label extension (cOLE) of the Phase 3 NefIgArd study.
HKEX Signs Cooperation Agreement with Indonesia Stock Exchange
Hong Kong Exchanges and Clearing Limited (HKEX) is today (Wednesday) pleased to announce it has signed a Memorandum of Understanding (MOU) with Indonesia Stock Exchange (IDX). The partnership will explore opportunities across a number of strategic areas that seek to support the mutual development of both organisations and their corresponding markets.
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust. Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year
Big Pharma Bets Big on China
Western drugmakers have aligned themselves with Beijing’s health priorities and are tapping local startups for innovative medicines
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has received approval from China Center for Drug Evaluation (CDE) to initiate Phase II clinical trial of TST002(Blosozumab).
